Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension

Journal of Cardiovascular Pharmacology
Tomohiro KatoKatsuaki Ito

Abstract

It is suggested that angiotensin II is involved in the pathogenesis of pulmonary hypertension and subsequent right ventricular hypertrophy; therefore, an angiotensin AT1 receptor antagonist could be beneficial for the treatment of this disease. We tested the effect of the new AT1 receptor antagonist olmesartan medoxomil on monocrotaline-induced pulmonary hypertension in rats. At 3 weeks after a single subcutaneous injection of monocrotaline (50 mg/kg), the lung/body weight ratio, the right ventricle/(left ventricle plus septum) weight ratio [RV/(LV+S)], and right ventricular systolic pressure were increased, indicating establishment of pulmonary hypertension and right ventricular hypertrophy. Oral administration of olmesartan medoxomil (2 or 5 mg/kg/day for 3 weeks) restored RV/(LV+S) and right ventricular systolic pressure, and a higher dose (5 mg/kg/day) improved the lung/body weight ratio. Pulmonary arteries isolated from monocrotaline-treated rats exhibited an increase in basal tone in the resting state, indicating that they had intrinsic tone. Three weeks of treatment with olmesartan decreased this intrinsic tone. These data suggest that long-term treatment with olmesartan has beneficial effects on monocrotaline-induced pu...Continue Reading

References

Aug 1, 1995·Circulation Research·T YamazakiK Tobe
Jul 1, 1994·Toxicology and Applied Pharmacology·C C Yan, R J Huxtable
Mar 11, 1994·Toxicology·B el AzzouziY Thomas
Oct 16, 1995·European Journal of Pharmacology·M MizunoH Koike
Sep 10, 1998·American Journal of Respiratory and Critical Care Medicine·K OkadaM D Botney
Jul 14, 2001·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·H KoikeM Mizuno
Dec 26, 2001·Pharmacology & Therapeutics·T K Jeffery, J C Wanstall
Jul 19, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Christophe AdamyCatherine Chassagne
Aug 6, 2003·Circulation·Cairistine Grahame-ClarkePatrick Vallance
Feb 21, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Sukrutha VeerareddySandra T Davidge
Jun 25, 2004·Nature·Randy Schekman
Jul 10, 2004·Journal of Cardiovascular Pharmacology·Masahiro NishidaYasuo Matsumura
Aug 3, 2005·Respiratory Research·Nicholas W MorrellRay J Beddoes
Oct 4, 2005·The Journal of Clinical Investigation·Ralph Theo SchermulyFriedrich Grimminger
Dec 13, 2005·European Journal of Pharmacology·Takaaki NakamotoKenji Sorimachi
May 13, 2006·The Journal of Biological Chemistry·Shin-ichiro MiuraKeijiro Saku
Aug 29, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Shin-ichi UsuiKoichiro Kinugawa

❮ Previous
Next ❯

Citations

Aug 25, 2009·American Journal of Respiratory and Critical Care Medicine·Jun Yin, Wolfgang M Kuebler
Jun 23, 2018·The European Respiratory Journal·Christophe GuignabertMarc Lombès
Sep 15, 2009·American Journal of Physiology. Lung Cellular and Molecular Physiology·Kurt R StenmarkIvan F McMurtry
Jul 21, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Maria E CampianHanno L Tan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.